Literature DB >> 28948494

Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Steffen E Storck1, Claus U Pietrzik2.   

Abstract

The accumulation of the neurotoxin beta-amyloid (Aβ) is a major hallmark in Alzheimer's disease (AD). Aβ homeostasis in the brain is governed by its production and various clearance mechanisms. Both pathways are influenced by the ubiquitously expressed low-density lipoprotein receptor-related protein 1 (LRP1). In cerebral blood vessels, LRP1 is an important mediator for the rapid removal of Aβ from brain via transport across the blood-brain barrier (BBB). Here, we summarize recent findings on LRP1 function and discuss the targeting of LRP1 as a modulator for AD pathology and drug delivery into the brain.

Entities:  

Keywords:  Alzheimer's disease; LRP1; angiopeps; beta-amyloid; blood-brain barrier; choroid plexus; drug delivery; targeting

Mesh:

Substances:

Year:  2017        PMID: 28948494     DOI: 10.1007/s11095-017-2267-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  181 in total

1.  LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation.

Authors:  J Herz; D E Clouthier; R E Hammer
Journal:  Cell       Date:  1992-10-30       Impact factor: 41.582

Review 2.  Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system.

Authors:  Gabriel A Silva
Journal:  Ann N Y Acad Sci       Date:  2010-06       Impact factor: 5.691

3.  What lessons can be learned from failed Alzheimer's disease trials?

Authors:  Jeremy Toyn
Journal:  Expert Rev Clin Pharmacol       Date:  2015-04-10       Impact factor: 5.045

Review 4.  Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide.

Authors:  C Haass; D J Selkoe
Journal:  Cell       Date:  1993-12-17       Impact factor: 41.582

5.  Failed Alzheimer's trial does not kill leading theory of disease.

Authors:  Alison Abbott; Elie Dolgin
Journal:  Nature       Date:  2016-11-23       Impact factor: 49.962

6.  Brain endothelial cells produce amyloid {beta} from amyloid precursor protein 770 and preferentially secrete the O-glycosylated form.

Authors:  Shinobu Kitazume; Yuriko Tachida; Masaki Kato; Yoshiki Yamaguchi; Takashi Honda; Yasuhiro Hashimoto; Yoshinao Wada; Takashi Saito; Nobuhisa Iwata; Takaomi Saido; Naoyuki Taniguchi
Journal:  J Biol Chem       Date:  2010-10-15       Impact factor: 5.157

7.  Effects of ginkgo biloba extract EGb761 on expression of RAGE and LRP-1 in cerebral microvascular endothelial cells under chronic hypoxia and hypoglycemia.

Authors:  Fu-Ling Yan; Ying Zheng; Feng-Di Zhao
Journal:  Acta Neuropathol       Date:  2008-10-01       Impact factor: 17.088

Review 8.  Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease.

Authors:  Sergio T Ferreira; Mychael V Lourenco; Mauricio M Oliveira; Fernanda G De Felice
Journal:  Front Cell Neurosci       Date:  2015-05-26       Impact factor: 5.505

9.  Inhibition of ADAM10 promotes the clearance of Aβ across the BBB by reducing LRP1 ectodomain shedding.

Authors:  B Shackleton; F Crawford; C Bachmeier
Journal:  Fluids Barriers CNS       Date:  2016-08-08

10.  Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency.

Authors:  Jong Ah Kim; Tommaso Casalini; Davide Brambilla; Jean-Christophe Leroux
Journal:  Sci Rep       Date:  2016-09-29       Impact factor: 4.379

View more
  13 in total

1.  Influence of Matrix Metallopeptidase 9 on Beta-Amyloid Elimination Across the Blood-Brain Barrier.

Authors:  Ben Shackleton; Charis Ringland; Laila Abdullah; Michael Mullan; Fiona Crawford; Corbin Bachmeier
Journal:  Mol Neurobiol       Date:  2019-06-18       Impact factor: 5.590

Review 2.  Interactions of Lipids, Lipoproteins, and Apolipoproteins with the Blood-Brain Barrier.

Authors:  Elizabeth M Rhea; William A Banks
Journal:  Pharm Res       Date:  2021-09-13       Impact factor: 4.200

3.  The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM.

Authors:  Steffen E Storck; Anika M S Hartz; Jessica Bernard; Andrea Wolf; André Kachlmeier; Anne Mahringer; Sascha Weggen; Jens Pahnke; Claus U Pietrzik
Journal:  Brain Behav Immun       Date:  2018-07-21       Impact factor: 7.217

4.  The Blood-Brain Barrier in Alzheimer's Disease.

Authors:  Steffen E Storck; Anika M S Hartz; Claus U Pietrzik
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Amyloid-beta impairs insulin signaling by accelerating autophagy-lysosomal degradation of LRP-1 and IR-β in blood-brain barrier endothelial cells in vitro and in 3XTg-AD mice.

Authors:  Chaitanya Chakravarthi Gali; Elham Fanaee-Danesh; Martina Zandl-Lang; Nicole Maria Albrecher; Carmen Tam-Amersdorfer; Anika Stracke; Vinay Sachdev; Florian Reichmann; Yidan Sun; Afrim Avdili; Marielies Reiter; Dagmar Kratky; Peter Holzer; Achim Lass; Karunya K Kandimalla; Ute Panzenboeck
Journal:  Mol Cell Neurosci       Date:  2019-07-02       Impact factor: 4.314

Review 6.  A Fundamental Role for Oxidants and Intracellular Calcium Signals in Alzheimer's Pathogenesis-And How a Comprehensive Antioxidant Strategy May Aid Prevention of This Disorder.

Authors:  Mark F McCarty; James J DiNicolantonio; Aaron Lerner
Journal:  Int J Mol Sci       Date:  2021-02-21       Impact factor: 5.923

7.  Targeting Alzheimer's disease with multimodal polypeptide-based nanoconjugates.

Authors:  A Duro-Castano; C Borrás; V Herranz-Pérez; M C Blanco-Gandía; I Conejos-Sánchez; A Armiñán; C Mas-Bargues; M Inglés; J Miñarro; M Rodríguez-Arias; J M García-Verdugo; J Viña; M J Vicent
Journal:  Sci Adv       Date:  2021-03-26       Impact factor: 14.136

Review 8.  Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?

Authors:  Rachel M Barker; Jeff M P Holly; Kalina M Biernacka; Shelley J Allen-Birt; Claire M Perks
Journal:  Front Endocrinol (Lausanne)       Date:  2020-06-23       Impact factor: 5.555

Review 9.  Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics.

Authors:  Maryam Raeeszadeh-Sarmazdeh; Linh D Do; Brianne G Hritz
Journal:  Cells       Date:  2020-05-25       Impact factor: 6.600

10.  APOE genotype moderates the relationship between LRP1 polymorphism and cognition across the Alzheimer's disease spectrum via disturbing default mode network.

Authors:  Feifei Zang; Yao Zhu; Qianqian Zhang; Chang Tan; Qing Wang; Chunming Xie
Journal:  CNS Neurosci Ther       Date:  2021-08-12       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.